Literature DB >> 8160022

Viral hepatitis in pregnancy.

J Simms1, P Duff.   

Abstract

Hepatitis A is usually a benign, self-limited infection. A chronic carrier state does not exist, and perinatal transmission does not occur. Hepatitis B may cause chronic infection, and infants delivered to infected mothers are at considerable risk of developing neonatal hepatitis. Passive and active immunization with HBIG and HBV is highly effective in preventing perinatal transmission. Hepatitis D typically occurs as a coinfection or superinfection with hepatitis B. Patients infected with both viruses are at high risk for chronic liver disease. Perinatal transmission of hepatitis D can be prevented by the immunoprophylaxis used for hepatitis B. Non-A, non-B hepatitis occurs in two distinct forms: parenterally transmitted hepatitis C and enterically transmitted hepatitis E. Perinatal transmission of hepatitis C can occur, particularly in women who are concurrently infected with the human immunodeficiency virus. Neonatal immunoprophylaxis is not yet available. Hepatitis E may be associated with high maternal mortality rates in developing nations. However, a chronic carrier state does not exist, and perinatal transmission does not occur. Table 2 summarizes the most important features of each form of viral hepatitis.

Entities:  

Mesh:

Year:  1993        PMID: 8160022

Source DB:  PubMed          Journal:  Semin Perinatol        ISSN: 0146-0005            Impact factor:   3.300


  2 in total

1.  Prevalence study of different hepatitis markers among pregnant Albanian refugees in Greece.

Authors:  A Malamitsi-Puchner; S Papacharitonos; D Sotos; L Tzala; M Psichogiou; A Hatzakis; A Evangelopoulou; S Michalas
Journal:  Eur J Epidemiol       Date:  1996-06       Impact factor: 8.082

2.  Innate immune function in placenta and cord blood of hepatitis C--seropositive mother-infant dyads.

Authors:  Christine Waasdorp Hurtado; Lucy Golden-Mason; Megan Brocato; Mona Krull; Michael R Narkewicz; Hugo R Rosen
Journal:  PLoS One       Date:  2010-08-30       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.